(Q41530932)

2 October 2017

1 reference

title

The skeletal effects of primary hyperparathyroidism (English)

1 reference

2 October 2017

1 reference

Grey AB

1

1 reference

2 October 2017

publication date

1 April 1997

1 reference

Bailliere's clinical endocrinology and metabolism

2 October 2017

published in

1 reference

2 October 2017

volume

11

1 reference

2 October 2017

issue

1

1 reference

2 October 2017

page(s)

101-116

1 reference

Specific binding of parathyroid hormone to living osteoclasts

2 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Evidence for alteration of the vitamin D-endocrine system in obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Prevalence of hypercalcaemia in a health screening in Stockholm

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Prediction of rapid bone loss in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Primary hyperparathyroidism: iliac crest cortical thickness, structure and remodeling evaluated by histomorphometric methods. Aarhus Bone and Mineral Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Back Pain and Vertebral Crush Fractures: An Unemphasized Mode of Presentation for Primary Hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Primary hyperparathyroidism: aggressive or conservative treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Bone histomorphometry and serum concentrations of intact parathyroid hormone (PTH(1-84)) in patients with primary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Trabecular bone remodeling and balance in primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Treatment with with oestrogens of primary hyperparathyroidism in post-menopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Changes in bone mass and metabolism after surgery for primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Regulation of cytokine expression in osteoblasts by parathyroid hormone: rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Body weight and bone mineral density in hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Body weight and bone mineral density in postmenopausal women with primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption--a clinical research center study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Accelerated bone loss in post-menopausal women with mild primary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Influence of body weight on rates of change in bone density of the spine, hip, and radius in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Measurement of the subcutaneous fat in the distal forearm by single photon absorptiometry.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Clinical use of bone densitometry

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Fracture incidence in postmenopausal women with primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Serum intact parathyroid hormone in a random population sample of men and women: relationship to anthropometry, life-style factors, blood pressure, and vitamin D

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Increased fracture risk in hypercalcemia. Bone mineral content measured in hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

The risk of hip fractures in patients with primary hyperparathyroidism: a population-based cohort study with a follow-up of 19 years

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Sequential changes in bone density before and after parathyroidectomy in primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Effect of parathyroid hormone on release of interleukin 1 and interleukin 6 from cultured mouse osteoblastic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Parathyroid hormone stimulates release of insulin-like growth factor-I (IGF-I) and IGF-II from neonatal mouse calvaria in organ culture

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Diabetes mellitus, glucose tolerance and insulin response to glucose in patients with primary hyperparathyroidism before and after parathyroidectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Treatment of postmenopausal osteoporosis with transdermal estrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Effects of mild asymptomatic primary hyperparathyroidism on bone mass in women with and without estrogen replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Conjugated Estrogens in the Treatment of Postmenopausal Women with Hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Partially reversible osteopenia after surgery for primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Long-term irreversibility of bone loss after surgery for primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Bone mineral content in patients with primary hyperparathyroidism: a comparison of conservative management with surgical treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Primary hyperparathyroidism: changes in the pattern of clinical presentation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Axial bone mass in older women. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Modulation of transforming growth factor-beta production in normal human osteoblast-like cells by 17 beta-estradiol and parathyroid hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Prevalence of hypercalcaemia in a health survey: a 14-year follow-up study of serum calcium values

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Endogenous production of tumor necrosis factor by primary cultures of murine calvarial cells: influence on IL-6 production and osteoclast development

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Serum levels of intact parathyroid hormone and alkaline phosphatase correlate with cortical and trabecular bone loss in primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Clinical Review 9: Management of asymptomatic hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Bone mineral changes in primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Hypercalcemia: long-term follow-up with matched controls

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Stimulation of interleukin-6 production by either calcitonin gene-related peptide or parathyroid hormone in two phenotypically distinct bone marrow-derived murine stromal cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Aminopropylidine diphosphonate (APD) in mild primary hyperparathyroidism: effect on clinical status

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Differential effects of endocrine dysfunction on the axial and the appendicular skeleton

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Skeletal disease in primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Clinical findings in patients with hypercalcaemia. A final investigation based on biochemical screening

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Serum osteocalcin levels and bone alkaline phosphatase isoenzyme after oophorectomy and in primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Time to end a conservative treatment for mild hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Parathyroid hormone binding to cultured avian osteoclasts

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Trabecular bone structure in patients with primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2897%2980537-X

7 January 2021

10.1016/S0950-351X(97)80537-X

Identifiers

DOI

1 reference

2 October 2017

1 reference